- Early 먹튀없는 바카라사이트 아톰카지노 data of TU2218 and ‘Keytruda’ combination therapy surpasses current standard treatments
- Active patient registration underway; expansion of 먹튀없는 바카라사이트 아톰카지노 sites in the U.S. planned for H2 2025, with full-scale global development in the works
[by Kang, In Hyo] Tiumbio announced on June 4 that it has revealed partial clinical data from the phase 2 clinical trial evaluating the combination therapy of ‘TU2218 (development code)’ and ‘Keytruda,’ currently under development.
The 먹튀없는 바카라사이트 아톰카지노 trial was designed to verify the potential synergistic effect of increasing the response rate of Keytruda by simultaneously administering TU2218 and Keytruda to modulate the tumor microenvironment and activate immune responses. This trial was introduced during the Trials in Progress (TPS) session at the 2025 American Society of 먹튀없는 바카라사이트 아톰카지노 Oncology (ASCO) Annual Meeting. The TPS session of ASCO 2025 serves as a venue to present the rationale, objectives, and design of ongoing 먹튀없는 바카라사이트 아톰카지노 trials. According to the company, it used this platform to share the initial data from this 먹튀없는 바카라사이트 아톰카지노 trial.
According to the disclosed early clinical data, in the head and neck squamous cell carcinoma (HNSCC) cohort in the first/second-line treatment group, 7 out of 11 evaluable patients exhibited a partial response (PR), while 1 patient demonstrated stable disease (SD). In the biliary tract cancer (BTC) cohort in the second-line treatment group, a significant ‘anti-tumor’ response was observed, with 4 out of 23 evaluable patients achieving a partial response and 7 patients maintaining stable disease (data cutoff: April 30, 2025).
Accordingly, the company stated that passing the first stage of the phase 2 clinical trial futility analysis represents a crucial milestone for the potential continuation of development. “We were able to engage in meaningful exchanges with leading figures in the global cancer market at the ASCO 2025 annual meeting,” expressed Kim Hun-taek, CEO of Tiumbio. “It is very encouraging to witness early indications of potential as a first- and second-line standard treatment for patients with head and neck cancer and bile duct cancer.”
“We are currently accelerating development by conducting biomarker analyses to validate the mechanism of future combination strategies and by expanding to major clinical institutions in the United States,” Kim further commented. “We are also in the process of identifying additional solid tumor types that may demonstrate therapeutic effects based on the mechanism of action of TU22218.”
Furthermore, the most commonly observed grade 1-2 treatment-related adverse events (TRAEs) in the aforementioned subjects included rash (approximately 10%), stomatitis (approximately 6.7%), and pruritus (approximately 6.7%). The company noted that most grade 3 or higher TRAEs, such as nausea (approximately 4%) and rash (approximately 4%), disappeared following temporary dose reductions of the investigational drug or administration of appropriate therapeutic interventions.
Tiumbio plans to continue monitoring the progress of the therapeutic efficacy and safety of the data presented in this announcement and to share updates at upcoming major oncology conferences, including the European Society of 먹튀없는 바카라사이트 아톰카지노 Oncology (ESMO), by incorporating follow-up data from additional enrolled patients as the 먹튀없는 바카라사이트 아톰카지노 trial progresses.
TU2218 is a dual inhibitor that simultaneously targets the pathways of ‘transforming growth factor (TGF-ß)’ and ‘vascular endothelial growth factor (VEGF),’ which are known to inhibit the activity of immunotherapy within the body. By doing so, it improves the tumor microenvironment and maximizes the efficacy of immunotherapies such as Keytruda. Currently, the TU2218 + Keytruda combination therapy is under development as a first- and second-line treatment option for head and neck cancer as well as biliary tract cancer, both of which have high unmet medical needs.